<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405040</url>
  </required_header>
  <id_info>
    <org_study_id>MIM-0906-0001</org_study_id>
    <nct_id>NCT01405040</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess Thermodilution Cardiac Output, Global End Diastolic Volume and Extravascular Lung Water</brief_title>
  <official_title>Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess TPTD, GEDV and EVLW</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to obtain the TPTD, GEDV and EVLW measurements from&#xD;
      existing indwelling femoral arterial Volume View™ catheter and central venous catheters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transpulmonary thermodilution has been proposed to measure transpulmonary thermodilution&#xD;
      cardiac output (TPTD), preload (GEDV, global end diastolic volume) and to quantify pulmonary&#xD;
      edema (EVLW, extravascular lung water). The method currently available on the market is based&#xD;
      on the estimation of time characteristics of the curve (mean transit time and down slope&#xD;
      time).&#xD;
&#xD;
      The purpose of this study is to evaluate a new transpulmonary thermodilution method to assess&#xD;
      the TPTD, EVLW and GEDV in patients requiring cardiac preload and lung water assessment. Up&#xD;
      to one hundred (100) patients will be enrolled at four (4) study sites, (up to 25 subjects at&#xD;
      each site). Hôpitaux Universitaires de Genève, Universität Bonn, Stadtspital Triemli Zürich,&#xD;
      and Universitätsklinikum Aachen will participate in the study.&#xD;
&#xD;
      This is a prospective, observational data collection study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TPTD, GEDV and EVLW measurements to evaluate the precision and accuracy of a novel algorithm in comparison to the widely accepted TPTD method</measure>
    <time_frame>Up to 72 hours of femoral arterial catheter dwell time.</time_frame>
    <description>This is not an outcome study. This is an observational Study to obtain TPTD, GEDV and EVLW data to evaluate the precision and accuracy of a novel algorithm in comparison to the widely accepted TPTD method using an approach defined by Bland-Altman.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Cardiac Output and Preload Assessment</condition>
  <condition>Lung Water Assessment</condition>
  <arm_group>
    <arm_group_label>EV1000 Observational Group</arm_group_label>
    <description>Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all ICU patients requiring cardiac preload and lung water&#xD;
        assessment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have clinical need for an indwelling femoral arterial catheter and&#xD;
             central venous catheter.&#xD;
&#xD;
          2. Patient, or legal guardian, must sign consent to be in the study prior to data&#xD;
             capture.&#xD;
&#xD;
          3. Patient must be at least 18 years old.&#xD;
&#xD;
          4. Patient height and weight are available prior to study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with significant aortic valve regurgitation.&#xD;
&#xD;
          2. Patients being treated with an intra-aortic balloon pump.&#xD;
&#xD;
          3. Patients less than 40 kg in weight.&#xD;
&#xD;
          4. Female patients with a known pregnancy or planned pregnancy.&#xD;
&#xD;
          5. Patient is currently participating in an investigational drug or another device study&#xD;
             that clinically interferes with the study endpoints.&#xD;
&#xD;
          6. Patients with peripheral vascular disease.&#xD;
&#xD;
          7. Patients with aortic aneurysm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Deyette, RN, CCRP</last_name>
    <role>Study Director</role>
    <affiliation>Edwards Lifesciences LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Pauwelsstrasse 30</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Der Rheinischen Friedrich-Wilhelms-Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Sigmund Freud Strasse 25</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli Zürich</name>
      <address>
        <city>Zürich</city>
        <state>Birmensdorferstr 497</state>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG-Hôpitaux Universitalres de Genève</name>
      <address>
        <city>Genève</city>
        <state>Geneva</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac</keyword>
  <keyword>Output</keyword>
  <keyword>Preload</keyword>
  <keyword>Lung</keyword>
  <keyword>Water</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

